Amgen's denosumab shows bone benefit in men
This article was originally published in Scrip
Amgen's denosumab increases bone mineral density and reduces fracture incidence in men undergoing androgen-deprivation therapy (ADT) for prostate cancer, top-line results from a pivotal Phase III study suggest.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.